Table 1 Comparison of baseline data before treatment between the two groups
Group | Chi-Square Tests(p-value) | t-test(p-value) | |||||
|---|---|---|---|---|---|---|---|
TACE + Sunitinib group(N = 47) | Sunitinib group(N = 51) | Pearson Chi-Square | Fisher’s Exact Test | ||||
Gender | Female | Count(%) | 11(23.4%) | 10(19.6%) | 0.806 | ||
Male | Count(%) | 36(76.6%) | 41(80.4%) | ||||
Pathological type | Clear cell carcinoma | Count(%) | 39(83.0%) | 40(78.4%) | 0.802 | ||
Papillary renal cell carcinoma | Count(%) | 5(10.6%) | 6(11.8%) | ||||
Chromophobe cell carcinoma | Count(%) | 3(6.4%) | 5(9.8%) | ||||
Venous tumor thrombus | None | Count(%) | 16(34.0%) | 21(41.2%) | 0.534 | ||
Yes | Count(%) | 31(66.0%) | 30(58.8%) | ||||
Distant metastasis | None | Count(%) | 10(21.3%) | 15(29.4%) | 0.487 | ||
Yes | Count(%) | 37(78.7%) | 36(70.6%) | ||||
Pre-treatment ECOG | 0 | Count(%) | 17(36.2%) | 18(35.3%) | 0.490 | ||
1 | Count(%) | 24(51.1%) | 22(43.1%) | ||||
2 | Count(%) | 6(12.8%) | 11(21.6%) | ||||
Pre-treatment liver function | Child A | Count(%) | 38(80.9%) | 40(78.4%) | 0.807 | ||
Child B | Count(%) | 9(19.1%) | 11(21.6%) | ||||
IMDC risk classification | Low Risk | Count(%) | 26(55.3%) | 24(47.1%) | 0.664 | ||
Intermediate risk | Count(%) | 18(38.3%) | 22(43.1%) | ||||
High risk | Count(%) | 3(6.4%) | 5(9.8%) | ||||
Age(Years) | Mean ± SD | 58.5 ± 9.1 | 55.8 ± 12.9 | 0.245 | |||
Pre-treatment bilirubin(µmol/L) | Mean ± SD | 12.3 ± 2.6 | 11.4 ± 3.0 | 0.124 | |||
Pretreatment Albumin(g/L) | Mean ± SD | 37.62 ± 2.42 | 38.42 ± 3.37 | 0.182 | |||
Pretreatment BUN(mmol/L) | Mean ± SD | 6.34 ± 1.43 | 6.07 ± 1.41 | 0.352 | |||
Pretreatment Cr(µmol/L) | Mean ± SD | 87.4 ± 21.1 | 89.4 ± 17.7 | 0.606 | |||
Pretreatment GFR(ml/min) | Mean ± SD | 107.06 ± 8.29 | 104.58 ± 8.81 | 0.155 | |||
Pretreatment WBC(G/L) | Mean ± SD | 4.43 ± 0.72 | 4.63 ± 0.62 | 0.133 | |||
Pretreatment RBC(T/L) | Mean ± SD | 4.39 ± 0.44 | 4.53 ± 0.58 | 0.179 | |||
Pretreatment PLT(G/L) | Mean ± SD | 128.81 ± 19.93 | 124.67 ± 20.31 | 0.312 | |||